Diabetic Macular Edema (DME) Market Report 2026

Diabetic Macular Edema (DME) Market Overview

• Diabetic Macular Edema (DME) market size has reached to $4.88 billion in 2025 • Expected to grow to $6 billion in 2030 at a compound annual growth rate (CAGR) of 4.2% • Growth Driver: Rising Diabetes Prevalence And Its Impact On Eye Health • Market Trend: Innovations In Sustained Ocular Therapy Transform Vision Management • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Diabetic Macular Edema (DME) Market?

Diabetic macular edema (DME) is a complication of diabetes that occurs when fluid accumulates in the macula, the central part of the retina responsible for sharp vision. This swelling is caused by damaged blood vessels leaking fluid and proteins into the retinal tissue, leading to vision impairment or blindness if left untreated. DME is a common cause of vision loss in diabetic patients and is associated with diabetic retinopathy. The main treatments of diabetic macular edema (DME) are anti-VEGF therapy, corticosteroids, laser therapy, and surgical intervention. Anti-VEGF therapy works by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for abnormal blood vessel growth and retinal leakage, which contribute to diabetic macular edema (DME). The disease progresses through stages such as early stage, moderate stage, and advanced stage. Patient demographics are categorized by age group, including adults, elderly, and children. Routes of administration consist of intravitreal injection, topical, and systemic methods, and it is distributed by hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Diabetic Macular Edema (DME) Market Growth Forecast?

The diabetic macular edema (dme) market size is expected to see steady growth in the next few years. It will grow to $6 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to advancements in biologic therapies, expansion of ai-driven eye screening, growth of specialty eye clinics, increasing awareness of diabetic eye complications, aging diabetic population. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of advanced retinal imaging technologies, expansion of early diagnosis and monitoring programs, growing focus on vision preservation treatments, integration of AI-based ophthalmic screening.

Global Diabetic Macular Edema (DME) Market Segmentation

1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention 2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage 3) By Patient Demographics: Adults, Elderly, Children 4) By Route Of Administration: Intravitreal Injection, Topical, Systemic 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies 2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids 3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation 4) By Surgical Intervention: Vitrectomy, Membrane Peeling

What Is The Driver Of The Diabetic Macular Edema (DME) Market?

The increase in prevalence of diabetes is expected to drive the growth of the diabetic macular edema (DME) market going forward. The increasing prevalence of diabetes is attributed to factors such as sedentary lifestyles, unhealthy dietary habits, rising obesity rates, aging populations, and genetic predisposition. Diabetes causes diabetic macular edema by damaging retinal blood vessels, leading to leakage of fluid into the macula and resulting in swelling. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people globally were living with diabetes. This number is expected to more than double, reaching 1.3 billion people by 2050. Therefore, the increase in prevalence of diabetes is driving the growth of the diabetic macular edema (DME) industry.

Key Players In The Global Diabetic Macular Edema (DME) Market

Major companies operating in the diabetic macular edema (dme) market are Roche Holding AG, Bayer AG, Novartis AG, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Carl Zeiss AG, Topcon Corporation, Optos plc, Allergan plc, Chengdu Kanghong Pharmaceutical Group, Kodiak Sciences, Opthea Limited, Oxurion NV, Aerie Pharmaceuticals Inc, Coherus BioSciences, KalVista Pharmaceuticals Inc, Araim Pharmaceuticals Inc, Acucela Inc, Antisense Therapeutics Limited, BCN Peptides SA, Ampio Pharmaceuticals Inc, Oculis SA, ThromboGenics NV, EyePoint Pharmaceuticals Inc.

Global Diabetic Macular Edema (DME) Market Trends and Insights

Major companies operating in the diabetic macular edema (DME) market are focusing on incorporating sustained-delivery implant technology such as refillable ocular implants to enhance treatment durability, patient compliance, and vision-maintenance efficiency. Refillable ocular implants are devices surgically placed in the eye that continuously release medication over extended periods, enabling capabilities such as less frequent dosing, sustained therapeutic exposure, and reduced treatment burden. For instance, in February 2025, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, received approval for Susvimo (ranibizumab 100 mg/mL delivered via the port delivery platform), a refillable ocular implant designed to treat DME, featuring continuous delivery of ranibizumab, refill intervals as infrequent as twice per year, and non-inferior vision outcomes compared with monthly intravitreal injections. Susvimo improves patient adherence, reduces injection burden, and supports sustained vision preservation.

What Are Latest Mergers And Acquisitions In The Diabetic Macular Edema (DME) Market?

In July 2024, Merck & Co Inc, a US-based pharmaceutical company, acquired Eyebiotech Limited for $1.3 billion. This acquisition allows Merck & Co. to strengthen its portfolio, boost research capabilities, and secure access to Restoret (EYE-103), a promising treatment for diabetic macular edema (DME) and treatment-naive neovascular age-related macular degeneration (AMD), positioning the company to address significant unmet needs in ophthalmology. Eyebiotech Limited (EyeBio) is a UK-based biotechnology company specializing in ophthalmology.

Regional Outlook

North America was the largest region in the diabetic macular edema (DME) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diabetic Macular Edema (DME) Market?

The diabetic macular edema (DME) market consists of revenues earned by entities by providing services such as retinal imaging, fluorescein angiography, visual acuity testing, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic macular edema market includes sales of ranibizumab, aflibercep, fluocinolone acetonide intravitreal implant, and dexamethasone intravitreal implant. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diabetic Macular Edema (DME) Market Report 2026?

The diabetic macular edema (dme) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic macular edema (dme) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.